Ferulic acid is nephrodamaging while gallic acid is renal protective in long term treatment of chronic kidney disease

Chiung Chi Peng, Chiu Lan Hsieh, Hui Er Wang, Jin Yuan Chung, Kuan Chou Chen, Robert Y. Peng

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Backgrounds & aims: The long term therapeutic effect of ferulic acid (FA) and gallic acid (GA) in treatment of chronic kidney disease (CKD) has been lacking. Methods: Doxorubicin (DR, Adriamycin)-induced CKD rat model was established for this study. Results: DR significantly reduced levels of serum albumin, GOT, GPT, RBC, TNF-α, and urinary creatinine and elevated serum cholesterol, TG, BUN, creatinine, uric acid, WBC, platelet count, and IL-6. In DRCKD rats, FA and GA significantly increased kidney weight and glomerular volume. FA reduced glomerular filtration rate but GA did not. FA enhanced more collagen deposition than GA in renal cortex and glomeruli. Both FA and GA showed crucial hyperlipidemic activity. The inhibitory effects of FA and GA on MMP-2 were very comparable. GA suppressed MMP-2 more effectively than FA in DRCKD rats. Both FA and GA induced SOD elevation and MDA elimination. In DRCKD rats, Western blot analysis indicated that FA further up-regulated CD34, α-SMA, tissue pDGFR, p-PDGFR, and TGF-β; and down-regulated p-PI3K, and p-Akt. Since both PDGF-BB and TGF-β are considered to induce kidney prefibrosis stage, GA was proved to be more beneficial in this regard. Conclusions: GA tends to protect the CKD while FA is not recommended for the long term CKD therapy.

Original languageEnglish
Pages (from-to)405-414
Number of pages10
JournalClinical Nutrition
Volume31
Issue number3
DOIs
Publication statusPublished - Jun 2012

Fingerprint

ferulic acid
Gallic Acid
Chronic Renal Insufficiency
Kidney
Matrix Metalloproteinases
Doxorubicin
Creatinine

Keywords

  • α-SMA
  • Chronic kidney disease
  • Ferulic acid
  • Gallic acid
  • PDGF

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Nutrition and Dietetics

Cite this

Ferulic acid is nephrodamaging while gallic acid is renal protective in long term treatment of chronic kidney disease. / Peng, Chiung Chi; Hsieh, Chiu Lan; Wang, Hui Er; Chung, Jin Yuan; Chen, Kuan Chou; Peng, Robert Y.

In: Clinical Nutrition, Vol. 31, No. 3, 06.2012, p. 405-414.

Research output: Contribution to journalArticle

Peng, Chiung Chi ; Hsieh, Chiu Lan ; Wang, Hui Er ; Chung, Jin Yuan ; Chen, Kuan Chou ; Peng, Robert Y. / Ferulic acid is nephrodamaging while gallic acid is renal protective in long term treatment of chronic kidney disease. In: Clinical Nutrition. 2012 ; Vol. 31, No. 3. pp. 405-414.
@article{cd3a3668ef214462bbec527efd069282,
title = "Ferulic acid is nephrodamaging while gallic acid is renal protective in long term treatment of chronic kidney disease",
abstract = "Backgrounds & aims: The long term therapeutic effect of ferulic acid (FA) and gallic acid (GA) in treatment of chronic kidney disease (CKD) has been lacking. Methods: Doxorubicin (DR, Adriamycin)-induced CKD rat model was established for this study. Results: DR significantly reduced levels of serum albumin, GOT, GPT, RBC, TNF-α, and urinary creatinine and elevated serum cholesterol, TG, BUN, creatinine, uric acid, WBC, platelet count, and IL-6. In DRCKD rats, FA and GA significantly increased kidney weight and glomerular volume. FA reduced glomerular filtration rate but GA did not. FA enhanced more collagen deposition than GA in renal cortex and glomeruli. Both FA and GA showed crucial hyperlipidemic activity. The inhibitory effects of FA and GA on MMP-2 were very comparable. GA suppressed MMP-2 more effectively than FA in DRCKD rats. Both FA and GA induced SOD elevation and MDA elimination. In DRCKD rats, Western blot analysis indicated that FA further up-regulated CD34, α-SMA, tissue pDGFR, p-PDGFR, and TGF-β; and down-regulated p-PI3K, and p-Akt. Since both PDGF-BB and TGF-β are considered to induce kidney prefibrosis stage, GA was proved to be more beneficial in this regard. Conclusions: GA tends to protect the CKD while FA is not recommended for the long term CKD therapy.",
keywords = "α-SMA, Chronic kidney disease, Ferulic acid, Gallic acid, PDGF",
author = "Peng, {Chiung Chi} and Hsieh, {Chiu Lan} and Wang, {Hui Er} and Chung, {Jin Yuan} and Chen, {Kuan Chou} and Peng, {Robert Y.}",
year = "2012",
month = "6",
doi = "10.1016/j.clnu.2011.11.003",
language = "English",
volume = "31",
pages = "405--414",
journal = "Clinical Nutrition",
issn = "0261-5614",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Ferulic acid is nephrodamaging while gallic acid is renal protective in long term treatment of chronic kidney disease

AU - Peng, Chiung Chi

AU - Hsieh, Chiu Lan

AU - Wang, Hui Er

AU - Chung, Jin Yuan

AU - Chen, Kuan Chou

AU - Peng, Robert Y.

PY - 2012/6

Y1 - 2012/6

N2 - Backgrounds & aims: The long term therapeutic effect of ferulic acid (FA) and gallic acid (GA) in treatment of chronic kidney disease (CKD) has been lacking. Methods: Doxorubicin (DR, Adriamycin)-induced CKD rat model was established for this study. Results: DR significantly reduced levels of serum albumin, GOT, GPT, RBC, TNF-α, and urinary creatinine and elevated serum cholesterol, TG, BUN, creatinine, uric acid, WBC, platelet count, and IL-6. In DRCKD rats, FA and GA significantly increased kidney weight and glomerular volume. FA reduced glomerular filtration rate but GA did not. FA enhanced more collagen deposition than GA in renal cortex and glomeruli. Both FA and GA showed crucial hyperlipidemic activity. The inhibitory effects of FA and GA on MMP-2 were very comparable. GA suppressed MMP-2 more effectively than FA in DRCKD rats. Both FA and GA induced SOD elevation and MDA elimination. In DRCKD rats, Western blot analysis indicated that FA further up-regulated CD34, α-SMA, tissue pDGFR, p-PDGFR, and TGF-β; and down-regulated p-PI3K, and p-Akt. Since both PDGF-BB and TGF-β are considered to induce kidney prefibrosis stage, GA was proved to be more beneficial in this regard. Conclusions: GA tends to protect the CKD while FA is not recommended for the long term CKD therapy.

AB - Backgrounds & aims: The long term therapeutic effect of ferulic acid (FA) and gallic acid (GA) in treatment of chronic kidney disease (CKD) has been lacking. Methods: Doxorubicin (DR, Adriamycin)-induced CKD rat model was established for this study. Results: DR significantly reduced levels of serum albumin, GOT, GPT, RBC, TNF-α, and urinary creatinine and elevated serum cholesterol, TG, BUN, creatinine, uric acid, WBC, platelet count, and IL-6. In DRCKD rats, FA and GA significantly increased kidney weight and glomerular volume. FA reduced glomerular filtration rate but GA did not. FA enhanced more collagen deposition than GA in renal cortex and glomeruli. Both FA and GA showed crucial hyperlipidemic activity. The inhibitory effects of FA and GA on MMP-2 were very comparable. GA suppressed MMP-2 more effectively than FA in DRCKD rats. Both FA and GA induced SOD elevation and MDA elimination. In DRCKD rats, Western blot analysis indicated that FA further up-regulated CD34, α-SMA, tissue pDGFR, p-PDGFR, and TGF-β; and down-regulated p-PI3K, and p-Akt. Since both PDGF-BB and TGF-β are considered to induce kidney prefibrosis stage, GA was proved to be more beneficial in this regard. Conclusions: GA tends to protect the CKD while FA is not recommended for the long term CKD therapy.

KW - α-SMA

KW - Chronic kidney disease

KW - Ferulic acid

KW - Gallic acid

KW - PDGF

UR - http://www.scopus.com/inward/record.url?scp=84861346250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861346250&partnerID=8YFLogxK

U2 - 10.1016/j.clnu.2011.11.003

DO - 10.1016/j.clnu.2011.11.003

M3 - Article

VL - 31

SP - 405

EP - 414

JO - Clinical Nutrition

JF - Clinical Nutrition

SN - 0261-5614

IS - 3

ER -